Overview

Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Sunitinib